These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17979590)

  • 21. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
    Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S
    Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression.
    New AS; Buchsbaum MS; Hazlett EA; Goodman M; Koenigsberg HW; Lo J; Iskander L; Newmark R; Brand J; O'Flynn K; Siever LJ
    Psychopharmacology (Berl); 2004 Nov; 176(3-4):451-8. PubMed ID: 15160265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoxetine treatment of obsessive-compulsive disorder.
    Turner SM; Jacob RG; Beidel DC; Himmelhoch J
    J Clin Psychopharmacol; 1985 Aug; 5(4):207-12. PubMed ID: 3894437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
    Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
    Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoxetine (prozac) in depresion of adults.
    Kocur J; Rydzynski Z; Duszyk S; Gruszczynski W; Trendak W
    Homeost Health Dis; 1991; 33(5-6):295. PubMed ID: 18265505
    [No Abstract]   [Full Text] [Related]  

  • 26. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.
    Liebowitz MR; Hollander E; Schneier F; Campeas R; Hatterer J; Papp L; Fairbanks J; Sandberg D; Davies S; Stein M
    J Clin Psychopharmacol; 1989 Dec; 9(6):423-7. PubMed ID: 2687337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience.
    Riddle MA; Hardin MT; King R; Scahill L; Woolston JL
    J Am Acad Child Adolesc Psychiatry; 1990 Jan; 29(1):45-8. PubMed ID: 2295577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluoxetine-induced mania in an Asian patient.
    Pae CU; Lee CU; Lee SJ; Lee C; Paik IH
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):448-9. PubMed ID: 15298662
    [No Abstract]   [Full Text] [Related]  

  • 29. Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine.
    Wilkinson D
    J Psychopharmacol; 1999 Dec; 13(4):420-1. PubMed ID: 10667621
    [No Abstract]   [Full Text] [Related]  

  • 30. Fluoxetine versus placebo in advanced cancer outpatients.
    Alliot C
    J Clin Oncol; 2004 Jan; 22(1):204-5; author reply 206-8. PubMed ID: 14701790
    [No Abstract]   [Full Text] [Related]  

  • 31. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
    Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
    Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
    Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
    Yucel A; Yucel N; Ozcan H; Gulec M; Aydin A
    J Clin Psychopharmacol; 2015 Jun; 35(3):354-5. PubMed ID: 25822478
    [No Abstract]   [Full Text] [Related]  

  • 34. An open trial of fluoxetine for adolescents with bulimia nervosa.
    Kotler LA; Devlin MJ; Davies M; Walsh BT
    J Child Adolesc Psychopharmacol; 2003; 13(3):329-35. PubMed ID: 14642021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
    Tollefson GD; Sayler ME
    Depress Anxiety; 1996-1997; 4(6):294-311. PubMed ID: 9166658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U; Onder E
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ecchymoses as an adverse effect of fluoxetine treatment.
    Fountoulakis KN; Samolis S; Iacovides A; St Kaprinis G
    Psychiatry Res; 2007 Jul; 152(1):91-2. PubMed ID: 17445912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of psychogenic excoriation and obsessive compulsive disorder using aripiprazole and fluoxetine.
    Curtis AR; Richards RW
    Ann Clin Psychiatry; 2007; 19(3):199-200. PubMed ID: 17729023
    [No Abstract]   [Full Text] [Related]  

  • 40. Anxiety as a predictor of treatment outcome in children and adolescents with depression.
    Cheung A; Mayes T; Levitt A; Schaffer A; Michalak E; Kiss A; Emslie G
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):211-6. PubMed ID: 20578934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.